TRIM33 and cancer: CAM is an autoimmune disorder, wherein cancer-associated antibodies against transcriptional intermediary factor1-gamma (TIF-1γ) and NXP-2 may induce cross-immune reactions within the body, leading to skin and vascular damage, ultimately resulting in inflammatory reactions in the muscle tissue [48].